ArticleMolecular nutrition & food research2025
An Application of a Large-Scale, Data-Driven Approach to Prioritize Compound-Targeted Conditions in the Nutraceutical Space: Case Study of Quercefit
Article in Molecular nutrition & food research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An Application of a Large-Scale, Data-Driven Approach to Prioritize Compound-Targeted Conditions in the Nutraceutical Space: Case Study of QuercefitMolecular nutrition & food research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
In preventive healthcare, the demand for systematic identification of wellness-promoting natural compounds is rising. Quercetin, a phenolic compound found in various fruits and vegetables, is known for its antioxidant and anti-inflammatory properties, improving lipid profiles and metabolic dysfunctions in conditions like Type 2 diabetes and NAFLD. This study applies a novel adaptation of an in-silico drug repurposing methodology to quercetin, analyzing a gene expression signature library of over 800 diseases and 30 quercetin-related conditions to prioritize molecular targets. Our findings revealed a strong computational link between quercetin and hypercholesterolemia. To validate this, we conducted a proof-of-concept clinical study using a high-bioaccessibility quercetin formulation (Quercefit
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.